Tumor Biomarkers in Peripheral Blood Liquid Biopsy of Soft Tissue Sarcomas: Research Progress and Clinical Applications in the Era of Precision Medicine

Guo ZHAO; Liangjie SUN; Shuhang WANG; Ning LI

doi:10.3881/j.issn.1000-503X.16564

PDF(906 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (6) : 987-996. DOI: 10.3881/j.issn.1000-503X.16564

Tumor Biomarkers in Peripheral Blood Liquid Biopsy of Soft Tissue Sarcomas: Research Progress and Clinical Applications in the Era of Precision Medicine

Author information +

History +

Abstract

Soft tissue sarcomas represent a rare and highly heterogeneous category of malignant tumors,with the diagnosis and treatment contingent upon the precise identification of histopathological subtypes.Due to their complex molecular mechanisms and diverse clinical behaviors,histological classification methods sometimes struggle to accurately distinguish different subtypes,highlighting the need for effective biomarkers for early diagnosis.As an emerging technology,liquid biopsy provides real-time tumor dynamic information for the diagnosis,recurrence monitoring,and treatment effect evaluation of soft tissue sarcomas by analyzing biomarkers in body fluids.This article comprehensively reviews the advancements in the research and clinical application of tumor biomarkers in the liquid biopsy of soft tissue sarcomas.It emphasizes biomarkers such as circulating tumor cells,cell-free DNA,non-coding RNA,and extracellular vesicles.Although liquid biopsy has shown great potential in the study of soft tissue sarcoma biomarkers,its clinical application still faces the challenges of low sensitivity and specificity,difficulty in tracing tissue origin,and the need for integration of multi-omics techniques.In the future,it is necessary to further develop conventional,non-invasive,and highly specific liquid biopsy markers and incorporate multi-omics technology and other clinical detection methods to promote the precise diagnosis and treatment of soft tissue sarcomas.

Key words

soft tissue sarcoma / liquid biopsy / tumor biomarker / precision medicine

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Guo ZHAO , Liangjie SUN , Shuhang WANG , et al. Tumor Biomarkers in Peripheral Blood Liquid Biopsy of Soft Tissue Sarcomas: Research Progress and Clinical Applications in the Era of Precision Medicine[J]. Acta Academiae Medicinae Sinicae. 2025, 47(6): 987-996 https://doi.org/10.3881/j.issn.1000-503X.16564

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults:an update on the current state of histiotype-specific management in an era of personalized medicine[J]. CA Cancer J Clin, 2020, 70(3):200-229.DOI:10.3322/caac.21605. Cited in this article [1]

[2]	Ray-Coquard I, Serre D, Reichardt P, et al. Options for treating different soft tissue sarcoma subtypes[J]. Future Oncol, 2018, 14(10s):25-49.DOI:10.2217/fon-2018-0076. Cited in this article [1]

[3]	Zhang YC, Zhou Q, Wu YL. The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer[J]. J Hematol Oncol, 2017, 10(1):167.DOI:10.1186/s13045-017-0536-6. Cited in this article [1]

[4]	Alix-Panabieres C, Pantel K. Liquid biopsy:from discovery to clinical application[J]. Cancer Discov, 2021, 11(4):858-873.DOI:10.1158/2159-8290.CD-20-1311. Cited in this article [1]

[5]	Wei J, Liu X, Li T, et al. The new horizon of liquid biopsy in sarcoma:the potential utility of circulating tumor nucleic acids[J]. J Cancer, 2020, 11(18):5293-5308.DOI:10.7150/jca.42816. Cited in this article [1]

[6]	Dajsakdipon T, Siripoon T, Ngamphaiboon N, et al. Immunotherapy and biomarkers in sarcoma[J]. Curr Treat Options Oncol, 2022, 23(3):415-438.DOI:10.1007/s11864-022-00944-6. Cited in this article [1]

[7]	Ardakani AHG, Woollard A, Ware H, et al. Soft tissue sarcoma:recognizing a rare disease[J]. Cleve Clin J Med, 2022, 89(2):73-80.DOI:10.3949/ccjm.89a.21078. Cited in this article [1]

[8]	Pillozzi S, Bernini A, Palchetti I, et al. Soft tissue sarcoma:an insight on biomarkers at molecular,metabolic and cellular level[J]. Cancers, 2021, 13(12):3044.DOI:10.3390/cancers13123044. Cited in this article [1]

[9]	Hayes DF. Biomarker validation and testing[J]. Mol Oncol, 2015, 9(5):960-966.DOI:10.1016/j.molonc.2014.10.004. Cited in this article [1]

[10]	Li X, Seebacher NA, Hornicek FJ, et al. Application of liquid biopsy in bone and soft tissue sarcomas:present and future[J]. Cancer Lett, 2018, 439:66-77.DOI:10.1016/j.canlet.2018.09.012. Cited in this article [1]

[11]	van der Laan P, van Houdt WJ, van den Broek D, et al. Liquid biopsies in sarcoma clinical practice: where do we stand[J]. Biomedicines, 2021, 9(10):1315. DOI: 10.3390/biomedicines9101315. Cited in this article [1]

[12]	Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells:clinical validity and utility[J]. Int J Clin Oncol, 2017, 22(3):421-430.DOI:10.1007/s10147-017-1105-2. Cited in this article [1]

[13]	Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases[J]. Clin Cancer Res, 2004, 10(20):6897-6904.DOI:10.1158/1078-0432.CCR-04-0378. Cited in this article [1]

[14]	Lin DF, Shen LS, Luo M, et al. Circulating tumor cells:biology and clinical significance[J]. Signal Transduct Target Ther, 2021, 6(1):404.DOI:10.1038/s41392-021-00817-8. Cited in this article [1]

[15]	Lianidou ES, Markou A, Strati A. The role of CTCs as tumor biomarkers[J]. Adv Exp Med Biol, 2015, 867:341-367.DOI:10.1007/978-94-017-7215-0_21. Cited in this article [1]

[16]	Ravegnini G, Sammarini G, Serrano C, et al. Clinical relevance of circulating molecules in cancer:focus on gastrointestinal stromal tumors[J]. Ther Adv Med Oncol, 2019, 11:1758835919831902.DOI:10.1177/1758835919831902. Cited in this article [1]

[17]	Tombolan L, Rossi E, Zin A, et al. Pediatric sarcomas display a variable EpCAM expression in a histology-dependent manner[J]. Transl Oncol, 2020, 13(11):100846.DOI:10.1016/j.tranon.2020.100846. Cited in this article [1]

[18]	Nicolazzo C, Gradilone A. Significance of circulating tumor cells in soft tissue sarcoma[J]. Anal Cell Pathol(Amst), 2015, 2015:697395.DOI:10.1155/2015/697395. Cited in this article [1]

[19]	Chang L, Asatrian G, Dry SM, et al. Circulating tumor cells in sarcomas:a brief review[J]. Med Oncol, 2015, 32(1):430.DOI:10.1007/s12032-014-0430-9. Cited in this article [1]

[20]

Chinen

, Mello

, Abdallah

, et al. Isolation,detection,and immunomorphological characterization of circulating tumor cells(CTCs)from patients with different types of sarcoma using isolation by size of tumor cells:a window on sarcoma-cell invasion[J]. Onco Targets Ther, 2014, 7:1609-1617.DOI:10.2147/OTT.S62349.

Cited in this article [1]

[21]

Martín-Broto

, Pousa

, Brohl

, et al. Circulating tumor cells and biomarker modulation with olaratumab monotherapy followed by olaratumab plus doxorubicin:phase Ⅰb study in patients with soft-tissue sarcoma[J]. Mol Cancer Ther, 2021, 20(1):132-141.DOI:10.1158/1535-7163.Mct-20-0441.

Cited in this article [3]

[22]	Shaik MR, Sagar PR, Shaik NA, et al. Liquid biopsy in hepatocellular carcinoma:the significance of circulating tumor cells in diagnosis,prognosis,and treatment monitoring[J]. Int J Mol Sci, 2023, 24(13):10644.DOI:10.3390/ijms241310644. Cited in this article [1]

[23]	Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer:a report from the ESMO Precision Medicine Working Group[J]. Ann Oncol, 2022, 33(8):750-768.DOI:10.1016/j.annonc.2022.05.520. Cited in this article [1]

[24]	Namlos HM, Boye K, Meza-Zepeda LA. Cell-free DNA in blood as a noninvasive insight into the sarcoma genome[J]. Mol Aspects Med, 2020, 72:100827.DOI:10.1016/j.mam.2019.10.004. Cited in this article [1]

[25]	Smolle MA, Seidel MG, Kashofer K, et al. Precision medicine in diagnosis,prognosis,and disease monitoring of bone and soft tissue sarcomas using liquid biopsy:a systematic review[J]. Arch Orthop Trauma Surg, 2025, 145(1):121.DOI:10.1007/s00402-024-05711-w. Cited in this article [1]

[26]	Bui NQ, Nemat-Gorgani N, Subramanian A, et al. Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis[J]. Clin Cancer Res, 2023, 29(14):2612-2620.DOI:10.1158/1078-0432.CCR-23-0250. Cited in this article [1]

[27]	Hemming ML, Klega K, Rhoades J, et al. Detection of circulating tumor DNA in patients with leiomyosarcoma with progressive disease[J]. JCO Precis Oncol, 2019, 3(3):1-11.DOI:10.1200/Po.18.00235. Cited in this article [1]

[28]	Demoret B, Gregg J, Liebner DA, et al. Prospective evaluation of the concordance of commercial circulating tumor DNA alterations with tumor-based sequencing across multiple soft tissue sarcoma subtypes[J]. Cancers(Basel), 2019, 11(12):1829.DOI:10.3390/cancers11121829. Cited in this article [1]

[29]	Cortes-Ciriano I, Steele CD, Piculell K, et al. Genomic patterns of malignant peripheral nerve sheath tumor(MPNST)evolution correlate with clinical outcome and are detectable in cell-free DNA[J]. Cancer Discov, 2023, 13(3):654-671.DOI:10.1158/2159-8290.CD-22-0786. Cited in this article [1]

[30]	Eisenhardt AE, Schmid A, Esser J, et al. Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas[J]. Mol Cancer, 2022, 21(1):50.DOI:10.1186/s12943-022-01523-x. Cited in this article [1]

[31]	Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications[J]. Nat Rev Cancer, 2011, 11(10):726-734.DOI:10.1038/nrc3130. Cited in this article [1]

[32]	Widschwendter M, Evans I, Jones A, et al. Methylation patterns in serum DNA for early identification of disseminated breast cancer[J]. Genome Medicine, 2017, 9:115.DOI:10.1186/s13073-017-0499-9. Cited in this article [1]

[33]	Widschwendter M, Zikan M, Wahl B, et al. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer[J]. Genome Medicine, 2017, 9(1):116.DOI:10.1186/s13073-017-0500-7. Cited in this article [1]

[34]	Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology[J]. Nat Rev Genet, 2019, 20(2):71-88.DOI:10.1038/s41576-018-0071-5. Cited in this article [3]

[35]	Leung F, Kulasingam V, Diamandis EP, et al. Circulating tumor DNA as a cancer biomarker:fact or fiction[J]. Clin Chem, 2016, 62(8):1054-1060.DOI:10.1373/clinchem.2016.260331. Cited in this article [1]

[36]	Martin-Alonso C, Tabrizi S, Xiong K, et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies[J]. Science, 2024, 383(6680):eadf2341.DOI:10.1126/science.adf2341. Cited in this article [1]

[37]	Jagtap U, Anderson ES, Slack FJ. The emerging value of circular noncoding RNA research in cancer diagnosis and treatment[J]. Cancer Res, 2023, 83(6):809-813.DOI:10.1158/0008-5472.CAN-22-3014. Cited in this article [1]

[38]	Piano MA, Gianesello L, Grassi A, et al. Circulating miRNA-375 as a potential novel biomarker for active Kaposi’s sarcoma in AIDS patients[J]. J Cell Mol Med, 2019, 23(2):1486-1494.DOI:10.1111/jcmm.14054. Cited in this article [1]

[39]	Uotani K, Fujiwara T, Yoshida A, et al. Circulating microRNA-92b-3p as a novel biomarker for monitoring of synovial sarcoma[J]. Sci Rep, 2017, 7:14634.DOI:10.1038/s41598-017-12660-5. Cited in this article [1]

[40]	Zhang P, Huang L, Ma P, et al. Altered expressions of NF1 and NF1-related microRNAs as biomarkers in the diagnosis of undifferentiated pleomorphic sarcoma[J]. Front Genet, 2022, 13:870191.DOI:10.3389/fgene.2022.870191. Cited in this article [1]

[41]	Kosela-Paterczyk H, Paziewska A, Kulecka M, et al. Signatures of circulating microRNA in four sarcoma subtypes[J]. J Cancer, 2020, 11(4):874-882.DOI:10.7150/jca.34723. Cited in this article [2]

[42]	Asano N, Matsuzaki J, Ichikawa M, et al. A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes[J]. Nat Commun, 2019, 10:1299.DOI:10.1038/s41467-019-09143-8. Cited in this article [2]

[43]	Cimino PJ, Gutmann DH. Neurofibromatosis type 1[J]. Handb Clin Neurol, 2018, 148:799-811.DOI:10.1016/b978-0-444-64076-5.00051-x. Cited in this article [1]

[44]	Zhang P, Huang L, Li X, et al. NF1-related microRNA gene polymorphisms and the susceptibility to soft tissue sarcomas:a case-control study[J]. DNA Cell Biol, 2023, 42(5):229-238.DOI:10.1089/dna.2022.0552. Cited in this article [1]

[45]	Moonmuang S, Chaiyawat P, Jantrapirom S, et al. Circulating long non-coding RNAs as novel potential biomarkers for osteogenic sarcoma[J]. Cancers, 2021, 13(16):4214.DOI:10.3390/cancers13164214. Cited in this article [1]

[46]	Wen JJ, Ma YD, Yang GS, et al. Analysis of circulating long non-coding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma[J]. Eur Rev Med Pharmacol Sci, 2017, 21(3):498-503. Cited in this article [1]

[47]	Yang L, Liu G, Xiao S, et al. Long noncoding MT1JP enhanced the inhibitory effects of miR-646 on FGF2 in osteosarcoma[J]. Cancer Biother Radiopharm, 2020, 35(5):371-376.DOI:10.1089/cbr.2019.3328. Cited in this article [1]

[48]	Szilágyi M, Pös O, Márton E, et al. Circulating cell-free nucleic acids:main characteristics and clinical application[J]. Int J Mol Sci, 2020, 21(18):6827.DOI:10.3390/ijms21186827. Cited in this article [1]

[49]	Zhu KP, Zhang CL, Hu JP, et al. A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma[J]. Int J Biol Sci, 2018, 14(11):1513-1520.DOI:10.7150/ijbs.27523. Cited in this article [3]

[50]	Chellini L, Palombo R, Riccioni V, et al. Oncogenic dysregulation of circulating noncoding RNAs:novel challenges and opportunities in sarcoma diagnosis and treatment[J]. Cancers(Basel), 2022, 14(19):4677.DOI:10.3390/cancers14194677. Cited in this article [1]

[51]	Kim SH, MacIntyre DA, Sykes L, et al. Whole blood holding time prior to plasma processing alters microRNA expression profile[J]. Front Genet, 2021, 12:818334.DOI:10.3389/fgene.2021.818334. Cited in this article [2]

[52]	Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes:current knowledge of their composition,biological functions,and diagnostic and therapeutic potentials[J]. Biochim Biophys Acta Gen Subj, 2012, 1820(7):940-948.DOI:10.1016/j.bbagen.2012.03.017. Cited in this article [1]

[53]	Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer[J]. Cell, 2023, 186(8):1610-1626.DOI:10.1016/j.cell.2023.03.010. Cited in this article [1]

[54]	Yuan TZ, Huang XY, Woodcock M, et al. Plasma extracellular RNA profiles in healthy and cancer patients[J]. Sci Rep, 2016, 6:19413.DOI:10.1038/srep19413. Cited in this article [1]

[55]	Zhu L, Sun HT, Wang S, et al. Isolation and characterization of exosomes for cancer research[J]. J Hematol Oncol, 2020, 13(1):152.DOI:10.1186/s13045-020-00987-y. Cited in this article [1]

[56]	Min L, Shen J, Tu CQ, et al. The roles and implications of exosomes in sarcoma[J]. Cancer Metastasis Rev, 2016, 35(3):377-390.DOI:10.1007/s10555-016-9630-4. Cited in this article [1]

[57]	Di Paolo V, Paolini A, Galardi A, et al. Plasma-derived extracellular vesicles miR-335-5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma[J]. J Exp Clin Cancer Res, 2024, 43(1):282.DOI:10.1186/s13046-024-03197-3. Cited in this article [2]

[58]	Atay S, Wilkey DW, Milhem M, et al. Insights into the proteome of gastrointestinal stromal tumors-derived exosomes reveals new potential diagnostic biomarkers[J]. Mol Cell Proteomics, 2018, 17(3):495-515.DOI:10.1074/mcp.RA117.000267. Cited in this article [1]

[59]	Miller IV, Raposo G, Welsch U, et al. First identification of Ewing’s sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications[J]. Biol Cell, 2013, 105(7):289-303.DOI:10.1111/boc.201200086. Cited in this article [2]

[60]	Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis[J]. Nature, 2015, 527(7578):329-335.DOI:10.1038/nature15756. Cited in this article [1]

[61]	Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles(MISEV2023):from basic to advanced approaches[J]. J Extracell Vesicles, 2024, 13(2):e12404.DOI:10.1002/jev2.12404. Cited in this article [1]

[62]	中国研究型医院学会细胞外囊泡研究与应用专业委员会. 细胞外囊泡分离与检测技术专家共识[J]. 中华检验医学杂志, 2024, 47(8):852-863.DOI:10.3760/cma.j.cn114452-20240528-00278. Cited in this article [1]

[63]	Bettin B, van der Pol E, Nieuwland R. Plasma extracellular vesicle test sample to standardize flow cytometry measurements[J]. Res Pract Thromb Haemost, 2023, 7(4):100181.DOI:10.1016/j.rpth.2023.100181. Cited in this article [1]

[64]	Miwa S, Yamamoto N, Tsuchiya H. Sarcoma:molecular pathology,diagnostics,and therapeutics[J]. Int J Mol Sci, 2023, 24(6):5833.DOI:10.3390/ijms24065833. Cited in this article [2]

[65]	Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer current: status, challenges and future prospects[J]. Signal Transduct Target Ther, 2024,9(1):336. DOI: 10.1038/s41392-024-02021-w. Cited in this article [1]

[66]	Bonora G, Dong H, Dai C, et al. Abstract 6598:the development of a tumor-agnostic liquid biopsy assay for minimal residual disease detection and monitoring in cancers[J]. Cancer Res, 2023, 83(7_Supplement):6598.DOI:10.1158/1538-7445.AM2023-6598. Cited in this article [1]

[67]	Qi T, Pan M, Shi HJ, et al. Cell-free DNA fragmentomics:the novel promising biomarker[J]. Int J Mol Sci, 2023, 24(2):1503.DOI:10.3390/ijms24021503. Cited in this article [1]

[68]	Heitzer E, Haque IS, Roberts CES, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology[J]. Nat Rev Genet, 2018, 20(2):71-88.DOI:10.1038/s41576-018-0071-5. Cited in this article [1]

[69]

Runkel

, Braig

, Bogner

, et al. Non-invasive monitoring of neoadjuvant radiation therapy response in soft tissue sarcomas by multiparametric MRI and quantification of circulating tumor DNA-A study protocol[J]. PLoS One, 2023, 18(11):e0285580.DOI:10.1371/journal.pone.0285580.

Cited in this article [1]

[70]	Medin CR, Cardona K. Response evaluation of neoadjuvant therapies in sarcoma[J]. Curr Treat Options Oncol, 2023, 24(5):515-527.DOI:10.1007/s11864-023-01075-2. Cited in this article [1]